EBITDA: Income before interest, taxes, depreciation and amortization.
Xenon Pharmaceuticals Inc. (XENE) had EBITDA of $-109.16M for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-105.26M |
|
-- |
|
-- |
|
$109.77M |
|
$-109.77M |
|
$5.04M |
|
$-104.72M |
|
$-104.72M |
|
$-105.26M |
|
$-105.26M |
|
$-105.26M |
|
$-105.26M |
|
$-109.77M |
|
|
EBITDA |
$-109.16M |
79.25M |
|
79.25M |
|
$-1.31 |
|
$-1.31 |
|
| Balance Sheet Financials | |
$560.65M |
|
$8.72M |
|
$72.51M |
|
$633.16M |
|
$41.79M |
|
-- |
|
$9.61M |
|
$51.40M |
|
$581.76M |
|
$581.76M |
|
$581.76M |
|
80.01M |
|
| Cash Flow Statement Financials | |
$-279.12M |
|
$218.00M |
|
$117.11M |
|
$142.71M |
|
$199.16M |
|
$56.45M |
|
$53.71M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
13.42 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-279.92M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-18.09% |
|
-18.09% |
|
-16.62% |
|
-18.09% |
|
$7.27 |
|
$-3.53 |
|
$-3.52 |
|